vs
Side-by-side financial comparison of SOLENO THERAPEUTICS INC (SLNO) and SolarMax Technology, Inc. (SMXT). Click either name above to swap in a different company.
SOLENO THERAPEUTICS INC is the larger business by last-quarter revenue ($66.0M vs $46.6M, roughly 1.4× SolarMax Technology, Inc.). SOLENO THERAPEUTICS INC runs the higher net margin — 39.4% vs -1.9%, a 41.3% gap on every dollar of revenue.
SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.
SolarMax Technology, Inc. develops, manufactures and sells high-efficiency solar PV modules and clean energy systems. It serves residential, commercial and industrial clients in North America and key Asia-Pacific markets, offering installation and after-sales support to boost low-carbon energy use.
SLNO vs SMXT — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $66.0M | $46.6M |
| Net Profit | $26.0M | $-872.2K |
| Gross Margin | 98.3% | 2.7% |
| Operating Margin | 33.5% | -2.7% |
| Net Margin | 39.4% | -1.9% |
| Revenue YoY | — | 623.5% |
| Net Profit YoY | 134.0% | 77.7% |
| EPS (diluted) | $0.47 | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $46.6M | ||
| Q3 25 | $66.0M | $30.6M | ||
| Q2 25 | $32.7M | $6.9M | ||
| Q1 25 | — | $6.9M | ||
| Q4 24 | — | $6.4M | ||
| Q3 24 | — | $6.3M |
| Q4 25 | — | $-872.2K | ||
| Q3 25 | $26.0M | $-2.3M | ||
| Q2 25 | $-4.7M | $-1.9M | ||
| Q1 25 | — | $-1.3M | ||
| Q4 24 | — | $-3.9M | ||
| Q3 24 | — | $-9.6M |
| Q4 25 | — | 2.7% | ||
| Q3 25 | 98.3% | 3.1% | ||
| Q2 25 | 97.9% | 8.8% | ||
| Q1 25 | — | 20.5% | ||
| Q4 24 | — | 14.5% | ||
| Q3 24 | — | 19.9% |
| Q4 25 | — | -2.7% | ||
| Q3 25 | 33.5% | -6.9% | ||
| Q2 25 | -20.0% | -25.7% | ||
| Q1 25 | — | -16.7% | ||
| Q4 24 | — | -27.9% | ||
| Q3 24 | — | -158.4% |
| Q4 25 | — | -1.9% | ||
| Q3 25 | 39.4% | -7.4% | ||
| Q2 25 | -14.4% | -27.6% | ||
| Q1 25 | — | -18.7% | ||
| Q4 24 | — | -60.6% | ||
| Q3 24 | — | -152.0% |
| Q4 25 | — | $-0.02 | ||
| Q3 25 | $0.47 | $-0.04 | ||
| Q2 25 | $-0.09 | $-0.04 | ||
| Q1 25 | — | $-0.03 | ||
| Q4 24 | — | $-0.07 | ||
| Q3 24 | — | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $498.9M | $8.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $494.8M | $-12.2M |
| Total Assets | $599.9M | $91.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $8.0M | ||
| Q3 25 | $498.9M | $5.7M | ||
| Q2 25 | $286.8M | $1.9M | ||
| Q1 25 | — | $6.8M | ||
| Q4 24 | — | $7.1M | ||
| Q3 24 | — | $8.6M |
| Q4 25 | — | $-12.2M | ||
| Q3 25 | $494.8M | $-11.8M | ||
| Q2 25 | $240.1M | $-15.1M | ||
| Q1 25 | — | $-15.9M | ||
| Q4 24 | — | $-15.1M | ||
| Q3 24 | — | $-10.9M |
| Q4 25 | — | $91.3M | ||
| Q3 25 | $599.9M | $58.7M | ||
| Q2 25 | $332.3M | $38.2M | ||
| Q1 25 | — | $38.6M | ||
| Q4 24 | — | $38.6M | ||
| Q3 24 | — | $43.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $43.5M | $-2.5M |
| Free Cash FlowOCF − Capex | $43.5M | — |
| FCF MarginFCF / Revenue | 65.8% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | 1.67× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-2.5M | ||
| Q3 25 | $43.5M | $3.4M | ||
| Q2 25 | $-12.6M | $220.7K | ||
| Q1 25 | — | $-601.1K | ||
| Q4 24 | — | $-1.3M | ||
| Q3 24 | — | $203.6K |
| Q4 25 | — | — | ||
| Q3 25 | $43.5M | — | ||
| Q2 25 | $-12.6M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 65.8% | — | ||
| Q2 25 | -38.6% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | 1.67× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SLNO
Segment breakdown not available.
SMXT
| Yabucoa | $35.9M | 77% |
| Other | $10.7M | 23% |
